지혈재 및 조직 실란트 시장 : 제품 유형, 소재 유형, 용도, 최종사용자별 - 시장 예측(2026-2032년)

The Hemostats & Tissue Sealants Market is projected to grow by USD 17.80 billion at a CAGR of 12.74% by 2032.

Hemostats & Tissue Sealants Market Introduction

Hemostats and tissue sealants are essential surgical technologies used to control bleeding, reinforce closure, reduce fluid leakage, and support safer procedural outcomes across cardiovascular, orthopedic, general, neurological, obstetric, dental, and trauma care. Demand is supported by rising surgical volumes, aging populations with higher comorbidity burdens, increasing anticoagulant use, and the continued shift toward minimally invasive and complex procedures where rapid hemostasis is clinically valuable.

The market is shaped by established product classes such as thrombin-based hemostats, gelatin and collagen matrices, fibrin sealants, synthetic sealants, polysaccharide-based agents, and combination products. Purchasing decisions increasingly reflect clinical evidence, biocompatibility, ease of use, storage requirements, operating room efficiency, reimbursement fit, and compliance with regulatory expectations from agencies such as the U.S. FDA and European authorities under the Medical Device Regulation.

Transformative Shifts in the Hemostats & Tissue Sealants Landscape

The landscape is moving from standalone bleeding-control products toward integrated surgical solutions that improve workflow, reduce complications, and support value-based care. Hospitals are prioritizing products with predictable performance across anticoagulated, elderly, obese, and high-risk patients, while surgeons seek formulations that are fast-acting, resorbable, low-swelling, and compatible with minimally invasive delivery systems.

Regulatory rigor, hospital cost containment, and procurement consolidation are reshaping competition. Manufacturers are investing in evidence generation, differentiated biomaterials, shelf-stable and ready-to-use formats, and training programs that demonstrate measurable impact on operative time, transfusion needs, postoperative leakage, and reintervention risk. Sustainability, traceability, and supply reliability are also becoming stronger differentiators as health systems scrutinize packaging, sourcing, sterilization, cold-chain dependence, and resilience.

Cumulative Impact of Artificial Intelligence on Surgical Sealant Adoption

Artificial intelligence is beginning to influence hemostats and tissue sealants through smarter product development, surgical planning, quality management, and hospital utilization analytics. AI-enabled modeling can help developers evaluate biomaterial behavior, degradation profiles, adhesion strength, swelling potential, and biological interactions earlier in the design cycle, reducing reliance on trial-and-error experimentation.

In clinical operations, AI can support procedure-level inventory planning, product standardization, and identification of cases with elevated bleeding or leakage risk based on patient history, anticoagulant use, laboratory values, comorbidities, and procedure type. Over time, AI-assisted imaging, digital operating rooms, and robotic surgery platforms may further personalize when and where sealants are applied, improving consistency while maintaining surgeon oversight and clinical accountability.

Key Regional Insights Across Asia-Pacific, North America, Europe & Emerging Regions

Asia-Pacific is gaining momentum as China, India, Japan, South Korea, and Australia expand surgical capacity and adopt advanced biomaterials, supported by aging demographics, higher chronic disease burden, medical tourism, and growing private healthcare investment. North America remains a high-value region due to advanced hospital infrastructure, established trauma systems, reimbursement maturity, strong adoption of premium surgical technologies, and high use of hemostatic agents in complex cardiovascular, orthopedic, spine, and oncology procedures.

Latin America shows selective growth led by Brazil and Mexico, where access expansion, private hospitals, and specialist surgical centers drive uptake despite budget constraints and uneven reimbursement. Europe emphasizes clinical evidence, post-market surveillance, and MDR compliance, with hospitals increasingly focused on procurement standardization and outcome-based value. The Middle East is investing in specialty care hubs, transplant programs, trauma systems, and advanced surgical infrastructure, while Africa remains opportunity-led, with adoption tied to surgical access, distributor networks, training capacity, affordability, and the availability of reliable hospital procurement channels.

Key Group Insights for ASEAN, GCC, EU, BRICS, G7 & NATO Markets

ASEAN is benefiting from medical tourism, hospital modernization, and rising procedure volumes in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines, although adoption varies with reimbursement and hospital purchasing maturity. The GCC is investing in tertiary hospitals, transplant programs, oncology centers, trauma care, and advanced surgical specialties, creating demand for premium hemostatic agents and tissue sealants that support complex procedures and faster surgical workflows.

The European Union is defined by MDR-driven evidence standards, clinical evaluation requirements, vigilance expectations, and centralized procurement pressures. BRICS offers scale through China, India, Brazil, Russia, and South Africa, but requires pricing flexibility, local regulatory expertise, public-sector access strategies, and dependable distribution partnerships. G7 markets lead in innovation adoption, surgeon training, and evidence-based product selection, while NATO countries also value trauma readiness, emergency surgery resilience, stockpile planning, and defense-related surgical preparedness.

Key Country Insights Across Major Surgical Markets

The United States leads adoption through high surgical complexity, strong trauma care, advanced ambulatory and inpatient infrastructure, and broad access to innovative hemostats and tissue sealants, while Canada emphasizes evidence-based purchasing, public-sector value, and formulary discipline. Mexico and Brazil are driven by private hospitals, expanding procedural access, and demand from cardiovascular, orthopedic, bariatric, and trauma care settings.

In Europe, the United Kingdom show steady demand supported by aging populations, specialized surgery, and hospital protocols focused on blood management, while Russia remains influenced by localization, import policy, and public procurement priorities. China form the Asia-Pacific opportunity base, with China and India offering procedural scale, Japan and South Korea emphasizing quality, safety, and innovation, and Australia favoring regulated, evidence-backed adoption through public and private hospital systems.

Actionable Recommendations for Hemostats & Tissue Sealants Leaders

Industry leaders should prioritize clinical differentiation by generating procedure-specific evidence that links hemostats and tissue sealants to reduced bleeding, shorter operative time, lower transfusion requirements, lower complication risk, reduced leakage, and improved workflow efficiency. Products should be positioned around measurable surgical value rather than commodity price, especially in cardiovascular, spine, liver, bariatric, thoracic, trauma, obstetric, and minimally invasive procedures.

Companies should also strengthen regional strategies through local regulatory expertise, distributor quality controls, surgeon education, hospital economic models, and reliable post-market surveillance. Portfolio planning should include ready-to-use formats, combination technologies, low-swelling materials, robotic-compatible applicators, and cost-effective options for emerging markets. AI-enabled utilization analytics, inventory planning, and real-world evidence generation can further improve supply reliability, product standardization, and clinical confidence.

Research Methodology for Market Intelligence This executive summary is developed through secondary research, regulatory review, competitive intelligence, and synthesis of publicly available healthcare, demographic, and surgical practice indicators. Sources considered include medical device regulatory frameworks, hospital procurement trends, peer-reviewed surgical literature, public health data, clinical guidelines, surgical blood management practices, and public disclosures relevant to hemostats, tissue sealants, and adjacent wound closure technologies.

The methodology emphasizes triangulation across clinical need, adoption drivers, regional healthcare infrastructure, reimbursement environment, product innovation, regulatory requirements, and competitive positioning. Insights are validated through consistency checks against established surgical trends, including population aging, growth in minimally invasive procedures, higher prevalence of chronic disease, increased anticoagulant use, and increasing pressure on hospitals to improve outcomes while managing operating room costs.

Conclusion: Evidence-Led Growth in Hemostats & Tissue Sealants

The hemostats and tissue sealants market is evolving from a product-led category into a clinically strategic segment of surgical care. Adoption is reinforced by the need for rapid bleeding control, secure tissue closure, reduced leakage, lower transfusion burden, and more efficient operating room performance across both mature and emerging healthcare systems.

Future advancement will depend on evidence-backed innovation, regulatory readiness, surgeon confidence, supply resilience, and the ability to align products with value-based healthcare objectives. Organizations that combine biomaterial science, AI-supported development, regional execution, and procedure-specific education will be best positioned to capture demand in this increasingly competitive surgical technology market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Hemostats & Tissue Sealants Market, by Product Type

• 7.1. Hemostats
  • 7.1.1. Active Hemostats
  • 7.1.2. Flowable Hemostats
  • 7.1.3. Mechanical Hemostats
• 7.2. Tissue Sealants
  • 7.2.1. Fibrin Sealants
  • 7.2.2. Synthetic Sealants

8. Hemostats & Tissue Sealants Market, by Material Type

• 8.1. Natural Materials
  • 8.1.1. Bovine-Derived
  • 8.1.2. Human-Derived
  • 8.1.3. Collagen-Based
  • 8.1.4. Gelatin-Based
• 8.2. Synthetic Materials
  • 8.2.1. Polyethylene Glycol-Based
  • 8.2.2. Cyanoacrylate-Based
  • 8.2.3. Polyurethane-Based

9. Hemostats & Tissue Sealants Market, by Application

• 9.1. Non-Surgical Procedures
  • 9.1.1. Diagnostic Procedures
  • 9.1.2. Minor Wound Sealing
• 9.2. Surgical Procedures
  • 9.2.1. Cardiovascular Surgery
  • 9.2.2. Gastrointestinal Surgery
  • 9.2.3. General Surgery

10. Hemostats & Tissue Sealants Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Clinics
• 10.3. Hospitals

11. Hemostats & Tissue Sealants Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Hemostats & Tissue Sealants Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Hemostats & Tissue Sealants Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. Adhezion Biomedical, LLC
• 15.3. Advanced Medical Solutions Group PLC
• 15.4. Aegis Lifesciences Private Limited.
• 15.5. Arch Therapeutics, Inc.
• 15.6. B. Braun SE
• 15.7. Baxter International Inc.
• 15.8. Becton, Dickinson and Company
• 15.9. Cardinal Health, Inc.
• 15.10. Chemence Medical, Inc.
• 15.11. CooperSurgical, Inc.
• 15.12. CryoLife, Inc.
• 15.13. CSL Behring
• 15.14. CuraMedical B.V.
• 15.15. EndoClot Plus, Inc.
• 15.16. Ferrosan Medical Devices A/S
• 15.17. Grifols, S.A.
• 15.18. Hemostasis, LLC
• 15.19. Hologic, Inc.
• 15.20. Integra LifeSciences Corporation
• 15.21. Johnson & Johnson Services, Inc.
• 15.22. KAKEN PHARMACEUTICAL CO., LTD.
• 15.23. KATSAN Katgut Sanayi ve Tic. A.S.
• 15.24. Medline Industries, LP.
• 15.25. Medtronic PLC
• 15.26. Olympus Corporation
• 15.27. Owens & Minor
• 15.28. Pfizer, Inc.
• 15.29. Smith & Nephew PLC
• 15.30. Stryker Corporation
• 15.31. Teleflex Incorporated
• 15.32. Terumo Corporation
• 15.33. Thermo Fisher Scientific Inc.
• 15.34. Vivostat A/S
• 15.35. Zimmer Biomet Holdings, Inc.